

CORPUS UTERI

Hospital Name/Address  Presbyterian Hospital of Dallas Texas Health Resources 8200 Walnut Hill Lane Dallas, Texas 75231

Patient Name/Information Patient name _____ Medical Record # _____ Date of Classification _____

Type of Specimen _____

Histopathologic Type _____

Tumor Size _____

DEFINITIONS

Clinical	Primary Tumor (T)
	<i>FIGO recommends surgical/pathologic staging. Clinical staging is done with 1971 FIGO as follows:</i>
	<i>TNM FIGO Definitions</i>
☐ (c)Tis 0	Carcinoma <i>in situ</i> . Histological findings suspicious of malignancy
☐ (c)T1 I	Carcinoma is confined to the corpus including the isthmus
☐ (c)T1a IA	Length of the uterine cavity is 8 cm or less
☐ (c)T1b IB	Length of the uterine cavity is more than 8 cm
	<i>Stage I cases should be subgrouped with regard to the histological type of the adenocarcinoma as follows:</i>
☐ G1	Highly differentiated adenomatous carcinoma
☐ G2	Moderately differentiated adenomatous carcinoma with partly solid areas
☐ G3	Predominately solid or entirely undifferentiated carcinoma
☐ (c)T2 II	Carcinoma has involved the corpus and the cervix, but has not extended outside the uterus
☐ (c)T3 III	Carcinoma has extended outside the uterus, but not outside the true pelvis
☐ (c)T4 IV	Carcinoma has extended outside the true pelvis or has obviously involved the mucosa of the bladder or rectum (Bullous edema as such does not permit a case to be allotted to stage IV)
☐ (c)T4a IVA	Spread of the growth to adjacent organs as urinary bladder, rectum, sigmoid colon, or small bowel
	<i>Stage 0 cases should not be included in any therapeutic statistics.</i>

Pathologic	Primary Tumor (T)
	<i>TNM FIGO Definitions</i>
☐ TX	Primary tumor cannot be assessed
☐ T0	No evidence of primary tumor
☐ Tis 0	Carcinoma <i>in situ</i>
☐ T1 I	Tumor confined to corpus uteri
☐ T1a IA	Tumor limited to endometrium
☐ T1b IB	Tumor invades less than one-half of the myometrium
☐ T1c IC	Tumor invades one-half or more of the myometrium
☐ T2 II	Tumor invades cervix but does not extend beyond uterus
☐ T2a IIA	Tumor limited to the glandular epithelium of the endocervix. There is no evidence of connective tissue stromal invasion
☐ T2b IIB	Invasion of the stromal connective tissue of the cervix
☐ T3 III	Local and/or regional spread as defined below
☐ T3a IIIA	Tumor involves serosa and/or adnexa (direct extension or metastasis) and/or cancer cells in ascites or peritoneal washings
☐ T3b IIIB	Vaginal involvement (direct extension or metastasis)
☐ T4 IVA	Tumor invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient evidence to classify a tumor as T4)

Clinical	Pathologic	Regional Lymph Nodes (N)
☐	☐	NX Regional lymph nodes cannot be assessed
☐	☐	N0 No regional lymph node metastasis
☐	☐	N1 IIIC Regional lymph node metastases to pelvic and/or para-aortic lymph nodes
		Distant Metastasis (M)
☐	☐	MX Distant metastasis cannot be assessed
☐	☐	M0 No distant metastasis
☐	☐	M1 IVB Distant metastasis includes metastasis to intra-abdominal lymph nodes other than para-aortic, and/or inguinal lymph nodes; excludes metastasis to vagina, pelvic serosa, or adnexa
		Biopsy of metastatic site performed ☐ Y ☐ N
		Source of pathologic metastatic specimen _____

<i>Clinical</i>	<i>Pathologic</i>	Stage Grouping (AJCC/UICC/FIGO)				Notes
☐	☐	0	Tis	N0	M0	Additional Descriptors
☐	☐	I	T1	N0	M0	Lymphatic Vessel Invasion (L)
☐	☐	IA	T1a	N0	M0	LX Lymphatic vessel invasion cannot be assessed
☐	☐	IB	T1b	N0	M0	L0 No lymphatic vessel invasion
☐	☐	IC	T1c	N0	M0	L1 Lymphatic vessel invasion
☐	☐	II	T2	N0	M0	Venous Invasion (V)
☐	☐	IIA	T2a	N0	M0	VX Venous invasion cannot be assessed
☐	☐	IIB	T2b	N0	M0	V0 No venous invasion
☐	☐	III	T3	N0	M0	V1 Microscopic venous invasion
☐	☐	IIIA	T3a	N	M0	V2 Macroscopic venous invasion
☐	☐	IIIB	T3b	N0	M0	
☐	☐	IIIC	T1	N1	M0	
			T2	N1	M0	
			T3	N1	M0	
☐	☐	IVA	T4	Any N	M0	
☐	☐	IVB	Any T	Any N	M1	

Histologic Grade (G)

- ☐ GX Grade cannot be assessed
- ☐ G1 Well differentiated
- ☐ G2 Moderately differentiated
- ☐ G3-G4 Poorly differentiated or undifferentiated

Histopathology—Degree of Differentiation

Cases of carcinoma of the corpus should be grouped with regard to the degree of differentiation of the adenocarcinoma as follows:

- ☐ G1 5% or less of a non-squamous or non-morular solid growth pattern
- ☐ G2 6% to 50% of a non-squamous or non-morular solid growth pattern
- ☐ G3 more than 50% of a non-squamous or non-morular solid growth pattern

Residual Tumor (R)

- ☐ RX Presence of residual tumor cannot be assessed
- ☐ R0 No residual tumor
- ☐ R1 Microscopic residual tumor
- ☐ R2 Macroscopic residual tumor

Additional Descriptors



For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

- ☐ **m suffix** indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
- ☐ **y prefix** indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy.
- ☐ **r prefix** indicates a recurrent tumor when staged after a disease-free interval, and is identified by the “r” prefix: rTNM.
- ☐ **a prefix** designates the stage determined at autopsy: aTNM.

Prognostic Indicators (if applicable)

ILLUSTRATION

Indicate on diagram primary tumor and regional nodes involved.

**Staging Support Request:**

___ Please fax staging form to my office for completion at fax # _____

___ Please assign staging form to Dr. _____

___ I am unable to stage at this time because workup is incomplete. Please return chart to me in 60 days.

Physician initials _____ Date _____

Staging Summary: T _____ N _____ M _____ Stage Group _____

Physician's Signature _____ Date _____